Ascentage Pharma FY26 H1 loss widens to US$120.4 million; revenue rises 29% to US$44.5 million

• Ascentage Pharma revenue rose 29% year over year to US$ 44.5 million for the six months ended June 30, 2026.
• Net loss widened to US$ 120.4 million; loss per share attributable to ordinary equity holders was US$ 0.32.
• Selling and distribution expenses climbed 64.3% to US$ 33.4 million, due to higher marketing and promotion investment for Lisaftoclax.
• R&D expenses increased 32% to US$ 102.8 million; cash and bank balances fell 23.3% to US$ 279.4 million.
• Added Dr. Faiçal Miyara as chief business officer and Jim Ziegler as chief commercial officer; nine registrational Phase III trials are ongoing globally.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608191900PRIMZONEFULLFEED9813209) on August 19, 2026, and is solely responsible for the information contained therein.